OLMA · Olema Pharmaceuticals Inc
United States · RS rating 15 · As of 2026-11-03
| Price | 7.35 USD |
|---|---|
| 1-day change | +4.0% |
| RS rating (overall / 1M / 3M / 12M) | 15 / 34 / 16 / 38 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 7 / 14 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -17.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +79.5% |
| Market cap (USD) | $1.3B |